US doctors and patients are split on approval of generic thyroid hormoneBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7459.192-b (Published 22 July 2004) Cite this as: BMJ 2004;329:192
- Janice Hopkins Tanne
- New York
Three groups representing 4600 US endocrinologists have said in a public statement that they are “deeply disappointed” that the Food and Drug Administration has approved generic substitutes for brandname levothyroxine. Patient groups have welcomed the news, however, with one group announcing on its website: “The Generics are Coming, The Generics are Coming!!!” (www.thyroid.about.com/od/thyroiddrugtreatments/a/generic.htm).
Levothyroxine is the second most commonly prescribed drug in the United States, with sales worth $1.19bn (£0.64bn; €0.96bn) in 2003. Abbott Laboratories' market leader, Synthroid, had sales of nearly $820m, says IMS Health, a major pharmaceutical information and consulting company. More than 13 million people take the drug.
The American Thyroid Association, the Endocrine Society, and the American Society of Clinical Endocrinologists said: “Small differences between doses—well within the range of formulation differences that might …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial